About this raise

Cytonics, with a valuation of $58.9 million, is raising funds on Dealmaker Securities. The company is a leader in regenerative medicine and has developed innovative therapies for musculoskeletal diseases like osteoarthritis. Cytonics has created an Autologous Platelet Integrated Concentration system concentrating A2M from patients’ blood to treat their own damaged joints. The company has a strong IP portfolio with 22 issued US and international patents. Gaetano Scuderi founded Cytonics Corporation in July 2006. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $1.9 million. The campaign proceeds will be used for GMP manufacturing of CYT-108, phase 1 human clinical trial, and working capital.

Expand

Investment Overview

Invested this round: $1,695,868

Deal Terms

Total Commitments

Platform
DealMaker Securities
Start Date
01/03/2023
Close Date
03/31/2023
Min. Goal
$25,000
Max Goal
$1,951,220
Min. Investment

$1,000

Security Type

Equity - Preferred

Company Stage

Growth Stage

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$2.30

Pre-Money Valuation

$58,915,995

Company & Team

Company

Year Founded
2006
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B/B2C
Margin
Low
Capital Intensity
High
Location
Jupiter, Florida
Business Type
Growth
Company Website
Visit Website

Team

Employees
3
Prior Founder Exits?
No
Founder Name
Gaetano Scuderi
Title
Chairman of the Board

Financials

 Revenue -47.9% YoY
$307,500
as of FY2021
 Monthly Burn
$1,878,682
as of FY2021
 Runway
0.5 months
as of FY2021

Summary Profit and Loss Statement

FY 2021 FY 2020

Revenue

$307,500

$591,056

COGS

$2,205,358

$503,906

Tax

$0

$0

 

 

Net Income

$-22,544,189

$-995,850

Summary Balance Sheet

FY 2021 FY 2020

Cash

$967,757

$537,354

Accounts Receivable

$341,193

$283,676

Total Assets

$1,756,758

$1,466,746

Short-Term Debt

$554,929

$2,400,661

Long-Term Debt

$0

$107,502

Total Liabilities

$554,929

$2,508,163

Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Total Prior Capital Raised
$22,000,000
Grants
$1,600,000
VC Backed?
Yes
Close Date Platform Valuation Total Raised Security Type Status Reg Type
03/14/2026 StartEngine $104,080,000 $2,448,845 Equity - Common Active RegA+
08/25/2024 StartEngine $66,557,294 $938,436 Equity - Preferred Funded RegCF
05/28/2024 StartEngine $65,792,080 $3,626,034 Equity - Preferred Funded RegCF
03/31/2023 DealMaker Securities $58,915,995 $1,695,868 Equity - Preferred Funded RegCF
10/14/2022 SeedInvest $58,915,996 $2,633,766 Equity - Preferred Funded RegCF / RegD 506(c)
04/30/2021 SeedInvest $46,701,000 $4,667,638 Equity - Preferred Funded RegA+
05/18/2019 SeedInvest $32,400,000 $494,344 Convertible Note Funded RegCF / RegD 506(c)
Create a free account today to gain access to Kingscrowd analytics.

Growth Charts

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Cytonics on Dealmaker Securities 2023
Platform: DealMaker Securities
Security Type: Equity - Preferred
Valuation: $58,915,995
Price per Share: $2.30

Follow company

Follow Cytonics on Dealmaker Securities 2023

Buy Cytonics's Deal Report

Warning: according to the close date for this deal, Cytonics may no longer be accepting investments.

Cytonics Deal Report

Get Kingscrowd's comprehensive report on Cytonics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Cytonics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Cytonics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge